secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0000950170-24-074280
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024
--------------------------------------------------------------------------------

- Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.
- Established Medicare price is $950 per test; distinct CPT codes published in CMS 2024 Clinical Lab Fee Schedule.
- Coverage applies to patients with Type 2 diabetes and Stage 1-3b Chronic Kidney Disease per FDA label.
- LCD issued by National Government Services (NGS), a Medicare Administrative Contractor for the company's NYC lab.
- CEO expects coverage to prompt additional major insurance decisions and accelerate test adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024074280/0000950170-24-074280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024074280/rnlx-20240614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-074280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer